FTSE All-Share
4.594,05
PKT
+16,93
PKT
+0,37
%
Werbung
Analysen zu FTSE All-Share-Werten
Datum | Rating | Analyst | |
---|---|---|---|
11.02.25 | BP Buy | Jefferies & Company Inc. | |
11.02.25 | BP Underweight | JP Morgan Chase & Co. | |
11.02.25 | BP Buy | UBS AG | |
11.02.25 | AstraZeneca Outperform | Bernstein Research | |
11.02.25 | Glencore Outperform | RBC Capital Markets | |
11.02.25 | Diageo Sector Perform | RBC Capital Markets | |
10.02.25 | BAT Buy | UBS AG | |
10.02.25 | GSK Hold | Deutsche Bank AG | |
10.02.25 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
10.02.25 | Diageo Neutral | JP Morgan Chase & Co. | |
10.02.25 | Unilever Sell | UBS AG | |
10.02.25 | BP Sector Perform | RBC Capital Markets | |
10.02.25 | Rio Tinto Neutral | UBS AG | |
10.02.25 | BP Buy | Jefferies & Company Inc. | |
10.02.25 | BP Buy | Jefferies & Company Inc. | |
07.02.25 | AstraZeneca Halten | DZ BANK | |
07.02.25 | BP Sector Perform | RBC Capital Markets | |
07.02.25 | GSK Outperform | Bernstein Research | |
07.02.25 | AstraZeneca Hold | Deutsche Bank AG | |
07.02.25 | BP Underweight | JP Morgan Chase & Co. | |
07.02.25 | GSK Underweight | JP Morgan Chase & Co. | |
07.02.25 | GSK Neutral | Goldman Sachs Group Inc. | |
06.02.25 | London Stock Exchange (LSE) Buy | UBS AG | |
06.02.25 | GSK Hold | Deutsche Bank AG | |
06.02.25 | AstraZeneca Neutral | UBS AG | |
06.02.25 | AstraZeneca Hold | Jefferies & Company Inc. | |
06.02.25 | BAT Buy | UBS AG | |
06.02.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
06.02.25 | Rio Tinto Neutral | UBS AG | |
06.02.25 | GSK Neutral | UBS AG | |
05.02.25 | GSK Neutral | Goldman Sachs Group Inc. | |
05.02.25 | Diageo Outperform | Bernstein Research | |
05.02.25 | Diageo Sell | Deutsche Bank AG | |
05.02.25 | GSK Outperform | Bernstein Research | |
05.02.25 | GSK Neutral | UBS AG | |
05.02.25 | BAT Neutral | Goldman Sachs Group Inc. | |
05.02.25 | Diageo Sell | Goldman Sachs Group Inc. | |
05.02.25 | Diageo Buy | UBS AG | |
03.03.25 | Vodafone Group Neutral | JP Morgan Chase & Co. | |
05.02.25 | Vodafone Group Neutral | JP Morgan Chase & Co. |